SBIR/STTR Research Award

Development of a Field-Ready Antimicrobial Wound Dressing for the Treatment of Vesicant Burns

Award identifier 19f9dbc20202fefb0ed99eadec94717b8c0f86dd2c9d908593c5439230a66719Awarding agency Department of Defense · Office for Chemical and Biological Defense

Award amount

$749,790

Program and phase

SBIR · Phase II

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Defense
Branch
Office for Chemical and Biological Defense
Recipient company
Stratatech Corporation
Proposal award date
2008-05-05
Contract end date
2010-05-05
UEI
WE88ZJ5AY3F9
Solicitation number
2007.1
Topic code
CBD07-113

Research abstract

Cutaneous wounds, such as those resulting from vesicant exposure and thermal injuries, provide an ideal environment for bacterial growth and the complications stemming from wound sepsis. The availability of ready-to-use, antimicrobial skin substitutes that are readily deployed in the field would provide immediate wound closure and reduce the incidence of infection in these wounds. To address these needs, Stratatech Corporation is developing a field-ready, tissue engineered antimicrobial therapeutic called EpiReadyDefense™ for treatment of vesicant, thermal and traumatic cutaneous injuries. This product is designed to contain elevated levels of naturally-occurring antimicrobial peptides in the context of a fully-stratified skin substitute that is ready to use and stable at ambient temperatures. During Phase II of the project, procedures will be developed to optimize Stratatech’s existing antimicrobial skin substitute for ambient storage. Efforts will focus on preserving tissue architecture and strength, as well as maintaining the antimicrobial properties required in the final product. The antimicrobial properties of EpiReadyDefense™ will be determined in an established animal model of burn wound infection. Phase II studies will also include preclinical, in vivo wound healing studies that will be required to support ultimate clinical evaluation and approval of EpiReadyDefense™ tissue.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

36 SBIR/STTR records share this UEI (2001–2015). Reported award amounts total $24,528,236. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense, National Science Foundation

Agency intelligence

Department of Defense

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.